New guidelines
U.S. guidelines for primary care and the general specialties published in the last 90 days, newest first. The list is checked every morning.
-
EASL-EASD-EASO Guidance for the Use of Resmetirom and Semaglutide as MASH-Targeted Therapy
The joint EASL-EASD-EASO guidance recommends resmetirom or semaglutide for adults with non-cirrhotic MASH and fibrosis stages 2-3, alongside lifestyle intervention and optimized comorbidity management. It addresses treatment selection, initiation, monitoring, and discontinuation, and advises against using these agents as MASH-targeted therapy in adults with MASH cirrhosis until further data are available.
-
AGA Clinical Practice Update on Surveillance of Pancreatic Cystic Lesions and Hepatocellular…
The AGA advises individualized decisions about pancreatic cyst and hepatocellular carcinoma surveillance in older adults, considering comorbidities, life expectancy, risks, and treatment candidacy. It recommends considering when to stop surveillance through shared decision-making.
-
2026 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management…
The ACC/AHA guideline recommends approaches to perioperative cardiovascular evaluation and management for adults undergoing noncardiac surgery, including pharmacological therapies, monitoring, and devices for cardiovascular disease and associated conditions.
-
Clinical Practice Guideline for the Diagnosis and Treatment of Urinary Tract Infection in Children…
The AAP guideline provides recommendations for diagnosing and managing urinary tract infections in children 8 days to 5 years of age with low medical complexity. It covers medical evaluation, antibiotic treatment, imaging, prevention strategies, and evaluation and treatment of bowel and bladder dysfunction.
-
2026 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management…
The ACC/AHA guideline recommends approaches to perioperative cardiovascular evaluation and management for adults undergoing noncardiac surgery, including evidence-based strategies for cardiovascular disease and associated conditions.
-
Tobacco Use Treatment: Synopsis of the 2026 U.S. Department of Veterans Affairs and U.S. Department…
The 2026 VA/DoD guideline recommends motivational interviewing and FDA-approved pharmacotherapies to increase abstinence from combustible tobacco, with varenicline preferred over other single-agent medications and combination NRT preferred over NRT alone. It also addresses treatment for smokeless tobacco, electronic nicotine delivery systems, and patients not ready to quit within 30 days.
-
AGA Clinical Practice Update on the Evaluation and Management of Metabolic Dysfunction- and…
The AGA recommends assessing alcohol use in all patients with steatotic liver disease, advising alcohol cessation, and using tiered noninvasive testing to assess fibrosis risk. For patients with MetALD, it also recommends lifestyle and cardiometabolic risk management and alcohol use disorder treatment when indicated.
-
2026 EASD evidence-based clinical practice guideline for assessing and managing diabetes distress…
EASD recommends routine, person-centred assessment and monitoring of diabetes distress among adults with type 1 or type 2 diabetes. It conditionally recommends specific psychological, technology-based, psychoeducational and educational interventions to reduce distress, depending on diabetes type.
-
American Society of Hematology 2026 guidelines for diagnosis of iron deficiency
The American Society of Hematology recommends serum ferritin thresholds for diagnosing iron deficiency in specific populations, whether or not anemia is present, and provides guidance for people with inflammation. The guidelines also discuss other diagnostic thresholds and research priorities.
These summaries are for general reference only. They are not official guidance and not medical advice. Guidelines are updated often, so check the issuing organization’s own website for the current version before relying on any recommendation.